Barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer: what's the problem?

ABSTRACT:

Introduction

The intravesical instillation of mitomycin C immediately following surgery for non-muscle invasive bladder cancer has been shown to be efficacious in reducing cancer recurrence. As a result, the American Urological Association adopted guidelines for non-muscle invasive bladder cancer care to support its use in low to intermediate risk patients. Despite this, urologists' use of this drug following transurethral resection of a bladder tumor (TURBT) has been reported as low as 5% or less. Our study objective was to better understand the barriers urologists experience in using mitomycin C.

Methods

Semi-structured interviews were conducted with 13 practicing urologists at 4 geographically distinct practice locations throughout Indiana between 2017 and 2018. Cognitive

SUBMITTER: Cary C 

PROVIDER: S-EPMC8130599 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature